These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23217192)

  • 1. Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital.
    Xu H; Cai H; Qian Z; Xu G; Yan X; Dai H
    BMC Cardiovasc Disord; 2012 Dec; 12():118. PubMed ID: 23217192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
    van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
    J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
    Cestac P; Bagheri H; Lapeyre-Mestre M; Sié P; Fouladi A; Maupas E; Léger P; Fontan B; Massip P; Montastruc JL
    Drug Saf; 2003; 26(3):197-207. PubMed ID: 12580648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER).
    Omran H; Bauersachs R; Rübenacker S; Goss F; Hammerstingl C
    Thromb Haemost; 2012 Jul; 108(1):65-73. PubMed ID: 22534746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy.
    Spyropoulos AC; Frost FJ; Hurley JS; Roberts M
    Chest; 2004 May; 125(5):1642-50. PubMed ID: 15136371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
    Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ;
    J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection.
    Canoglu K; Saylan B
    Ann Saudi Med; 2020; 40(6):462-468. PubMed ID: 33307734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifications of low-molecular weight heparin use in a French university hospital after implementation of new guidelines.
    Leclerc-Foucras S; Bagheri H; Samii K; Montastruc JL; Lapeyre-Mestre M;
    Drug Saf; 2007; 30(5):409-17. PubMed ID: 17472419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
    Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
    JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.
    Jaffer AK; Ahmed M; Brotman DJ; Bragg L; Seshadri N; Qadeer MA; Klein A
    J Thromb Thrombolysis; 2005 Aug; 20(1):11-6. PubMed ID: 16133889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice of bridging anticoagulation: guideline adherence and risk factors for bleeding.
    Eijgenraam P; ten Cate H; ten Cate-Hoek AJ
    Neth J Med; 2014 Apr; 72(3):157-64. PubMed ID: 24846933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset.
    Cooray C; Mazya M; Mikulik R; Jurak L; Brozman M; Ringleb P; Dixit A; Toni D; Ahmed N
    Stroke; 2019 May; 50(5):1149-1155. PubMed ID: 30943884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.